Skip to main content

Recombinant Human CCL4L1/MIP-1 beta Isoform LAG-1 Protein

R&D Systems, part of Bio-Techne | Catalog # 3046-MB

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
Carrier Free
3046-MB-025/CF

Catalog #
Availability
Size / Price
Qty
With Carrier
3046-MB-025

Key Product Details

Source

E. coli

Accession #

Conjugate

Unconjugated

Applications

Bioactivity

Product Specifications

Source

E. coli-derived human CCL4L1/LAG-1 protein
Ala24-Asn92

Purity

>95%, by SDS-PAGE under reducing conditions and visualized by silver stain.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Ala24

Predicted Molecular Mass

7.8 kDa

SDS-PAGE

12 kDa, reducing conditions

Activity

Measured by its ability to chemoattract BaF3 mouse pro-B cells transfected with human CCR5.
The ED50 for this effect is 0.5-2.5 ng/mL.

Formulation, Preparation and Storage

Carrier Free
What does CF mean?

CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.

What formulation is right for me?

In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.

Carrier: 3046-MB
Formulation Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Carrier Free: 3046-MB/CF
Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution Reconstitute at 100 μg/mL in sterile PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: CCL4L1/LAG-1

CCL4, also known as MIP-1 beta, is a 12 kDa beta chemokine that is secreted by activated leukocytes, lymphocytes, vascular endothelial cells, and pulmonary smooth muscle cells. CCL4 interacts with CCR5 to attract lymphocytes, NK cells, and immature dendritic cells to sites of inflammation (1 - 4). CCL4 also blocks the entry of HIV into CCR5-expressing cells (5). Human CCL4 and its variants are encoded by two paralogous genes(6 - 8), one of which (SCYA4) encodes CCL4 itself (9). The other gene (SCYA4L) is found in two alleles that give rise to CCL4L1 and CCL4L2, respectively (9). The human CCL4L1 cDNA encodes a 92 amino acid (aa) precursor with a 23 aa signal sequence. Alternate splicing yields an isoform with a 40 aa internal deletion. The second allele (SCYA4L2), encoding CCL4L2, is spliced into a variety of isoforms (9). Human CC4L1 shares greater than 98% aa sequence identity with CCL4 and CCL4L2. It shares 96% aa sequence identity with rhesus CCL4 and approximately 80 - 90% aa sequence identity with bovine, mouse, rabbit, and rat CCL4. The gene copy number for CCL4L1 varies from zero to five, but this is not associated with changes in mRNA or protein levels (10). CCL4 and CCL4L1 demonstrate comparable CCR5 binding, promotion of chemotaxis, and inhibition of HIV replication in stimulated PBMC (10, 11). In vivo, the first two N-terminal amino acids of CCL4 are removed by DPPIV. The truncated form is as active as full-length CCL4 and gains the ability to bind CCR1 and CCR2b (12, 13). Similar proteolytic processing of CCL4L1 has not been described.

References

  1. Maurer, M. and E. von Stebut (2004) Int. J. Biochem. Cell Biol. 36:1882.
  2. Menten, P. et al. (2002) Cytokine Growth Factor Rev. 13:455.
  3. Bisset, L.R. and P. Schmid-Grendelmeier (2005) Curr. Opin. Pulm. Med. 11:35.
  4. Frangogiannis, N.G. (2004) Inflamm. Res. 53:585.
  5. Lehner, T. (2002) Trends Immunol. 23:347.
  6. Modi, W.S. (2004) Genomics 83:735.
  7. Lu, J. et al. (2004) Immunogenetics 55:706.
  8. Modi, W.S. (2001) Immunogenetics 53:543.
  9. Colobran, R. et al. (2005) J. Immunol. 174:5655.
  10. Townson, J.R. et al. (2002) Eur. J. Immunol. 32:3016.
  11. Howard, O.M.Z. et al. (2004) Biochem. Biophys. Res. Commun. 320:927.
  12. Guan, E. et al. (2004) J. Cell. Biochem. 92:53.
  13. Guan, E. et al. (2002) J. Biol. Chem. 277:32348.

Alternate Names

LAG-1, LAG1, SCYA4L

Entrez Gene IDs

9560 (Human)

Gene Symbol

CCL4L2

UniProt

Additional CCL4L1/LAG-1 Products

Product Documents for Recombinant Human CCL4L1/MIP-1 beta Isoform LAG-1 Protein

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Human CCL4L1/MIP-1 beta Isoform LAG-1 Protein

For research use only

Loading...
Loading...
Loading...